双特异性抗体及抗体构建物在肿瘤学中的综述及临床挑战
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
机构信息
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
出版信息
Pharmacol Ther. 2019 Sep;201:103-119. doi: 10.1016/j.pharmthera.2019.04.006. Epub 2019 Apr 24.
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges.
双特异性抗体（bsAbs）是能够结合两种不同表位的抗体，用于癌症治疗。目前，已有一种 bsAb 获得批准，57 种 bsAbs 正在临床试验中，但均未进入 3 期。这些 bsAbs 在设计和作用机制上存在很大差异。不同的设计通常与作用机制相关。大多数 bsAbs 利用免疫细胞来杀伤肿瘤细胞。但是，一些 bsAbs 也用于向肿瘤输送有效载荷或阻断肿瘤信号通路。本文深入探讨了 bsAbs 构建体的选择，并总结了 bsAbs 在肿瘤学中的临床开发情况，同时指出了后续的挑战。
Zotero 插件